Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

500
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
500
Blinding01:11

Blinding

4.0K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

275
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
275
Hazard Ratio01:12

Hazard Ratio

650
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Estimand Framework in Diagnostic Accuracy Studies.

Statistics in medicine·2025
Same author

Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease Example.

Therapeutic innovation & regulatory science·2025
Same author

Reply to 'Bayesian approaches in drug development: continuing the virtuous cycle'.

Nature reviews. Drug discovery·2024
Same author

Sensitivity analysis for causality in observational studies for regulatory science.

Journal of clinical and translational science·2024
Same author

A causal roadmap for generating high-quality real-world evidence.

Journal of clinical and translational science·2023
Same author

Application of Bayesian approaches in drug development: starting a virtuous cycle.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Feb 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Considerations for Evaluating Treatment Effects From Randomized Clinical Trials.

Stephen J Ruberg1, Mouna Akacha2

  • 1Global Statistical Sciences and Advanced Analytics, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

Clinical Pharmacology and Therapeutics
|September 12, 2017
PubMed
Summary
This summary is machine-generated.

This study argues that traditional intention-to-treat (ITT) analysis in randomized clinical trials (RCTs) may not fully capture clinically meaningful treatment effects. It advocates for explicitly defining the primary "estimand" of interest to ensure accurate and relevant treatment effect measurement.

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Related Experiment Videos

Last Updated: Feb 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmacoeconomics

Background:

  • Randomized clinical trials (RCTs) traditionally employ intention-to-treat (ITT) analysis.
  • The implicit assumption is that the treatment-policy effect is of primary interest in ITT analyses.
  • Limitations exist in traditional ITT measures for accurately reflecting clinically meaningful treatment effects.

Purpose of the Study:

  • To challenge the adequacy of traditional ITT analysis for measuring treatment effects in RCTs.
  • To advocate for the explicit definition of the primary treatment effect of interest, termed the 'estimand'.
  • To explore alternative treatment effect measures that acknowledge the multifaceted nature of treatment effects.

Main Methods:

  • Critical review of traditional intention-to-treat (ITT) analysis in randomized clinical trials (RCTs).
  • Discussion of the concept and importance of 'estimands' in defining primary treatment effects.
  • Exploration of alternative treatment effect measures beyond traditional ITT.

Main Results:

  • Traditional ITT analysis may not always provide accurate information on clinically meaningful treatment effects.
  • Explicitly defining the 'estimand' is crucial for appropriate treatment effect measurement in RCTs.
  • Acknowledging multiple treatment effects necessitates considering alternative measurement approaches.

Conclusions:

  • The choice of treatment effect measure in RCTs requires careful consideration beyond standard ITT.
  • Defining the estimand ensures that the primary research question regarding treatment effects is clearly addressed.
  • Future research should focus on developing and validating alternative measures that capture the complexity of treatment effects.